Han X and colleagues reported that NLRP3 inflammasome activation correlates with PD progression, and could be inhibited by kaempferol via ubiquitination and autophagy, indicating that targeting NLRP3 is a promising therapeutic strategy for PD [28]. Here, NLRP3 is linked to Parkinson disease.